Teva Pharmaceutical Industries (NYSE:TEVA) Trading Up 8.2% After Analyst Upgrade

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) were up 8.2% during mid-day trading on Wednesday after Piper Sandler raised their price target on the stock from $42.00 to $44.00. Piper Sandler currently has an overweight rating on the stock. Teva Pharmaceutical Industries traded as high as $35.69 and last traded at $34.2610. 4,113,965 shares traded hands during mid-day trading, a decline of 43% from the average session volume of 7,208,451 shares. The stock had previously closed at $31.67.

A number of other research firms also recently weighed in on TEVA. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Barclays raised their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Truist Financial lifted their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Mark Sabag sold 144,180 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. This trade represents a 64.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Amir Weiss sold 10,679 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the sale, the chief accounting officer owned 20,016 shares of the company’s stock, valued at approximately $720,576. This trade represents a 34.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 465,931 shares of company stock worth $16,332,989 in the last 90 days. Company insiders own 0.54% of the company’s stock.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported second-quarter revenue of $4.14 billion, exceeding the $4.02 billion analyst consensus. More importantly, its key innovative brands grew 43% year over year in local-currency terms to more than $1 billion in combined revenue, and the company raised its 2026 outlook for all three brands. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: UZEDY sales reached a record $77 million in the second quarter, up 43% year over year. Teva raised its 2026 UZEDY revenue forecast to $270 million-$290 million from $250 million-$280 million, supporting the company’s shift toward higher-growth branded medicines. UZEDY Record Q2 Net Sales
• Positive Sentiment: Piper Sandler raised its price target on Teva to $44 from $42 and maintained an “overweight” rating, citing potential from the company’s branded drug pipeline. Piper Sandler Price Target Update
• Neutral Sentiment: Full-year 2026 revenue guidance of $16.5 billion-$16.9 billion is broadly consistent with the $16.7 billion analyst consensus, indicating improved expectations but not a major top-line surprise.
• Negative Sentiment: Adjusted EPS was $0.02, below the $0.08 consensus estimate, while revenue declined about 1% year over year because of weaker generics. Teva’s 2026 EPS outlook of $1.91-$2.11 is also below the $2.17 consensus, limiting the upside from the better branded-drug performance. Teva Second-Quarter Earnings Report

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently modified their holdings of the company. Aster Capital Management DIFC Ltd bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth $25,000. Cornerstone Planning Group LLC raised its holdings in Teva Pharmaceutical Industries by 547.1% in the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock worth $27,000 after acquiring an additional 755 shares during the period. Allworth Financial LP lifted its position in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in Teva Pharmaceutical Industries by 567.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after acquiring an additional 1,134 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

The company has a market capitalization of $39.53 billion, a P/E ratio of 25.85, a PEG ratio of 3.28 and a beta of 0.86. The stock’s fifty day simple moving average is $33.19 and its 200-day simple moving average is $32.68. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, July 29th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.06). Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $4.14 billion during the quarter, compared to the consensus estimate of $4.02 billion. During the same quarter in the previous year, the firm posted $0.66 earnings per share. The company’s revenue for the quarter was down .8% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 1.910-2.110 EPS. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.99 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.